CN101072765A - Phenylpiperazines with a combination of affinity for dopamine -D2 receptors and serotonin reuptake sites - Google Patents
Phenylpiperazines with a combination of affinity for dopamine -D2 receptors and serotonin reuptake sites Download PDFInfo
- Publication number
- CN101072765A CN101072765A CNA2005800420702A CN200580042070A CN101072765A CN 101072765 A CN101072765 A CN 101072765A CN A2005800420702 A CNA2005800420702 A CN A2005800420702A CN 200580042070 A CN200580042070 A CN 200580042070A CN 101072765 A CN101072765 A CN 101072765A
- Authority
- CN
- China
- Prior art keywords
- compound
- tautomer
- disease
- chain
- steric isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000697 serotonin reuptake Effects 0.000 title abstract description 11
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 title abstract description 8
- 102000004980 Dopamine D2 Receptors Human genes 0.000 title abstract 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 4
- -1 N-oxide compound Chemical class 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000001704 evaporation Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- 229960003638 dopamine Drugs 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000007039 two-step reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- MECRKILGNPUEFQ-UHFFFAOYSA-N o-(2-aminoethyl)hydroxylamine Chemical compound NCCON MECRKILGNPUEFQ-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 150000004885 piperazines Chemical class 0.000 description 3
- 235000007715 potassium iodide Nutrition 0.000 description 3
- 229960004839 potassium iodide Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 230000001519 thymoleptic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical group O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- ZEIPAQOMPRPQJR-UHFFFAOYSA-N o-[2-(methylamino)ethyl]hydroxylamine Chemical compound CNCCON ZEIPAQOMPRPQJR-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
Abstract
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula ( 1 ) wherein the symbols have the meanings given in the specification.
Description
The present invention relates to one group and have the dual function mode: serotonin reuptake inhibition and Dopamine HCL-D
2The neophyl bridged piperazine derivatives of the avidity of acceptor, and relate to the preparation method of these compounds.The invention still further relates to the application that compound disclosed herein is used to prepare the medicine that beneficial effect is provided.Beneficial effect discloses in this article or is conspicuous according to specification sheets and technology general knowledge to those skilled in the art.The invention still further relates to compound of the present invention and be used to prepare the application of the medicine of treatment or preventing disease or symptom.More particularly, the present invention relates to a kind of new application that is used for the treatment of disease or symptom, this disease or symptom disclose in this article or are conspicuous according to specification sheets and technology general knowledge for a person skilled in the art.In embodiments of the invention, specific compound disclosed herein is used for preparing to be used for the treatment of relating to Dopamine HCL-D
2Acceptor and serotonin reuptake sites or can be by operating the medicine of the disease that these targets treat.
Have as Dopamine HCL-D according to WO01/014330 is known
2The Phenylpiperazine derivatives of antagonist and serotonin reuptake inhibitor dual function.This combination can be used for treating schizophrenia and other mental disorder, thereby can treat more completely all disease symptomses (for example positive symptom and negative symptoms).
In patent specification GB1378080 (1974), openly has useful pharmacological activity, especially as pain killer, anti-inflammatory agent with to the 9 oxime derivate of the halogenophenyl piperazinyl-alkyl ketone of flesh spasmolytic.
The object of the present invention is to provide further and have as Dopamine HCL-D
2The compound of the dual function of antagonist and serotonin reuptake inhibitor.
The present invention relates to compound and tautomer, steric isomer and the N-oxide compound of general formula (1), and acceptable salt, hydrate and solvate on the pharmacology of the compound of this formula (1) and tautomer, steric isomer and N-oxide compound:
Wherein:
M and n are 1,2,3,4,5,6,7 or 8 independently,
X is 0,1,2 or 3,
R
2Be halogen, branched-chain or straight-chain alkyl (C
1-6), phenyl, benzyl, side chain or straight chain alkoxyl group (C
1-6), trifluoromethyl or cyano group,
R
3And R
4Represent hydrogen, alkyl (C independently
1-6), phenyl, benzyl or ethanoyl,
Group Q is selected from structure fragment A-N
Wherein:
Y is 1,2 or 3,
R
1Be halogen, branched-chain or straight-chain alkyl (C
1-6), phenyl, benzyl, side chain or straight chain alkoxyl group (C
1-6), trifluoromethyl or cyano group.
The prodrug of above-claimed cpd within the scope of the present invention.Prodrug is non-activity own but can changes into the therapeutical agent that one or more plant active metabolite.Prodrug is the biological reversible derivatization thing of drug molecule that is used to overcome some obstacle of parent drug molecular application.These obstacles include but not limited to solubleness, perviousness, stability, presystemic metabolism (presystemicmetabolism) and target restriction (Medicinal Chemistry:Principles andPractice, 1994, ISBN 0-85186-494-5, Ed.:F.D.King, p.215; J.Stella, " Prodrugs as therapeutics ",
Expert Opin.Ther. Patents, 14 (3), 277-280,2004; People such as P.Ettmayer, " Lessonslearned from marketed and investigational prodrugs ", J.Med.Chem., 47,2393-2404,2004).Prodrug promptly be metabolized to the have formula compound of compound of (1) during to people's administration by any known approach, belongs to the present invention.Especially, this relates to the compound with uncle or secondary amino group or hydroxyl.These compounds can with organic acid reaction obtain the having formula compound of (1), wherein there is the additional group of removing easily after the administration, such as but not limited to amidine (amidine), enamine, Mannich base (Mannich base), hydroxyl-methylene derivatives, O-(acyloxy methene amido manthanoate) derivative, carbamate, ester, acid amides or enamine ketone (enaminone).
The N-oxide compound of above-claimed cpd within the scope of the invention.Tertiary amine may produce or not produce N-oxide compound meta-bolites.The degree that the N-oxidation takes place is that trace is extremely near Quantitative yield.The N-oxide compound may be than their tertiary amine active greater or lesser of correspondence.Though the N-oxide compound becomes the tertiary amine of their correspondence easily by the chemical process reduction, this takes place with different degree in human body.Some N-oxide compound changes into corresponding tertiary amine near reducing quantitatively, and this conversion in other cases only is the trace reaction or even does not exist fully.(M.H.Bickel:“The pharmacology and Biochemistry of N-oxides”,
Pharmaco-logical Reviews,
21(4),325-355,1969)。
Compound and tautomer, steric isomer and the N-oxide compound of preferred compound of the present invention for having formula (1), and acceptable salt, hydrate and solvate on the pharmacology of the compound of this formula (1) and tautomer, steric isomer and N-oxide compound, wherein m is 1 in formula (1), n is 2,3,4 or 5, x is 1, R
2Be 4-fluorine or 4-trifluoromethyl, R
3And R
4Represent hydrogen or methyl independently, group Q is selected from structure fragment A, D, F or N, and y is 1, and R
1Be side chain or straight chain alkoxyl group (C
1-3).
Found that compound according to the present invention shows dopamine D
2Acceptor and serotonin reuptake sites all have the height avidity.This compound shows as dopamine D
2The activity of receptor antagonist is because their antagonism apomorphine (apomorphine) inductive mouse climbing behaviors potentially.This compound also shows the activity as the serotonin reuptake inhibitor, because they strengthen the behavior of 5-HTP inductive mouse.This compound is to the treatment model of clinical relevant antipsychotic drug sensitivity (CAR (conditionedavoidance response) for example; Van der Heyden ﹠amp; Bradford, Behav.BrainRes., 1988,31:61-67) and to the treatment model of thymoleptic or anxiolytic sensitivity (for example the sounding that brings out of pressure suppresses (suppression of stress-inducedvocalization); People such as van der Poel, Psycho-pharmacology, 1989, have activity in 97:147-148).With clinical relevant dopamine D
2Receptor antagonist is opposite, and described compound induces the cataleptic proneness of rodent little, and therefore compares with existing antipsychotic drug and may induce the outer side reaction of less pyramidal tract.The inhibition activity of these compound inherent serotonin reuptakes may cause observed result of treatment in to the behavior model of thymoleptic or anxiolytic sensitivity.This compound can be used for the treatment of central nervous system disorders or the disease that is caused by dopaminergic or serotonergic system obstacle, for example attack (aggression), anxiety disorder (anxiety disorders), autism (autism), dizzy (vertigo), depressed, cognition or dysmnesia, Parkinson's disease (Parkinson ' sdisease), particularly schizophrenia (schizophrenia) and other mental disorder.
Synthetic overview
The synthetic of all bridged piperazine derivatives in this patent can carry out as described in the preparation of compound 3 as scheme 1.The raw material phenylpiperazine can be as EP 0 189 612:Hartog, people such as J, 1985: ' New pharmaceutical compositions having a psychtropicactivity '; Feenstra, R.W.; De Moes, J.P; Hofma, J.; Kling, H.; Kuipers, W; Long, S.K.; Tulp, M.T.M.; Van der Heyden, J.A.M and Kruse, C.G.; ' New 1-ary1-4-(biarylmethylene) piperazines aspotential atypical antipsychotics sharing dopamine D
2Receptorand serotonin 5HT
1AReceptor affinities.Bioorg.﹠amp; Med.Chem.Lett., 2001,11, the described acquisition of 2345-2349 and WO01/14330.Alkyl phenyl ketone derivatives 2 is available commercially.
aReagent and condition: (i) DIPEA, KI, CH
3CN refluxes; (ii) H
2NO-CH
2CH
2NH
22HCl, DIPEA, EtOH refluxes
Factor well known by persons skilled in the art is depended in the selection of concrete synthetic method; the consistency of functional group and agents useful for same for example; use the possibility of protecting group, catalyzer, activation and coupling reagent, and the final constitutional features that exists in the final compound of preparation.
Can for example pass through compound of the present invention and suitable acid with well known to a person skilled in the art that standard method obtains pharmacy acceptable salt, for example mineral acid example hydrochloric acid or organic acid mix.
Pharmaceutical preparation
Can use auxiliary material such as liquid or solid solid support material compound of the present invention to be transformed into the form that is suitable for administration by conventional method.Pharmaceutical composition of the present invention can carry out intestines, mouth, parenteral (intramuscular or intravenously), rectum or zone (part) administration.They can be with solution, powder, tablet, capsule (comprising microcapsule), ointment (emulsifiable paste or gel) or suppository form administration.The suitable vehicle that is used for these preparations is pharmaceutically conventional liq or solid weighting agent and swelling agent, solvent, emulsifying agent, lubricant, seasonings, painted and/or buffer substance.The auxiliary material commonly used that can mention is magnesiumcarbonate, titanium dioxide, lactose, N.F,USP MANNITOL and other sugar, talcum, milk-protein, gelatin, starch, Mierocrystalline cellulose and its derivative, animal and plant oil as Oils,glyceridic,cod-liver, sunflower oil, peanut oil or sesame oil, polyoxyethylene glycol and solvent such as sterilized water and one or polyhydroxy-alcohol such as glycerine.
Compound of the present invention is generally as the pharmaceutical composition administration, and this pharmaceutical composition is owing to exist this compound, specific compound especially disclosed herein, thereby be important and new embodiment of the present invention.The type of operable pharmaceutical composition includes but not limited to other type that tablet, chewable tablet, capsule, solution, parenteral solution, suppository, suspension and disclosed herein or those skilled in the art obviously know according to specification sheets and technology general knowledge.In embodiments of the invention, provide a kind of drug packages or medicine box that comprises the container of one or more compositions of having filled one or more pharmaceutical compositions of the present invention.Relevant with these containers can be multiple written material, working instructions for example, perhaps by the mark of the government organs regulation of production, use or the sale of management medicine, this mark reflection is permitted producing, using or sell to be used for people or beastly administration by this mechanism.
Pharmacological method
To Dopamine HCL-D
2The external avidity of acceptor
Use I.Creese, R.Schneider and S.H.Snyder: " [
3H]-Spiroperidollabels dopamine receptors in rat pituitary and brain ", Eur.J.Pharmacol., 46,377-381,1977 described receptor binding assays are measured compound to Dopamine HCL-D
2The avidity of acceptor.
External avidity to the serotonin reuptake sites
With people such as E.Habert: " Characterisation of [
3H]-paroxetinebinding to rat cortical membranes ", Eur.J.Pharmacol., 118,107-114,1985 described receptor binding assays are measured the avidity of compound to the serotonin reuptake sites.
Dosage
As above-mentioned mensuration The compounds of this invention to Dopamine HCL-D
2The avidity of acceptor and serotonin reuptake sites.Can the estimation theory minimum effective dose according to binding affinity to the compound determination of the formula (1) determined.The K that is equaling to measure
iUnder the compound concentrations of-value twice, 100% acceptor may occupy by combined thing.Suppose the ideal bioavailability, this concentration is changed into mg compound/kg patient, obtain theoretical minimum effective dose.Pharmacokinetics, pharmacodynamics and other consideration may change to higher or lower value with actual dosage.Suitable dosage is 0.001-1000mg/kg, preferred 0.1-100mg/kg weight in patients.
Treatment
Term used herein " treatment " refers to Mammals, any treatment of preferred people's symptom or disease, comprise: (1) preventing disease or symptom are having ill tendency but the ill experimenter of N is taken place on one's body, (2) suppress disease or symptom, promptly stop its development, (3) palliate a disease or symptom, promptly cause disease to disappear, perhaps (4) symptom of palliating a disease and causing promptly stops the symptom of disease.
The preparation of the compound with formula (1) is described in following examples now in more detail.
Embodiment
Embodiment 1: material and method
On Bruker Avance DRX600 instrument (600MHz), Varian UN400 instrument (400MHz) or Varian VXR200 instrument (200MHz), use DMSO-D
6Or CDCl
3As solvent, and with tetramethylsilane as interior mark, record
1H and
13C NMR spectrum.With ppm (δ scale) is unit, provides chemical shift from the tetramethylsilane downfield.Coupling constant (J) is unit representation with Hz.(0.040-0.063mm Merck) carries out flash chromatography and handles (Flash chromatography) with silica gel 60.(0.063-0.200mm Merck) carries out column chromatography and handles with silica gel 60.On B ü chi B-545 fusing point instrument, measure fusing point.On the Micromass QTOF-2 instrument that has the MassLynx application software that is used to obtain and reproduce data, write down mass spectrum.Finish quasi-molecular ion [M+H]
+Exact mass measure.
Embodiment 2: synthetic particular compound
The synthetic of compound 3 is the two-step reaction that originates in 4-(2,3 dihydros-1,4 benzo dioxine-5-yl)-1-piperazine (3i).The piperazine (3i) of 15mmol is suspended in the 125ml acetonitrile, and adds 2 normal di-isopropyl ethyl-amine (DIPEA).Stir after 5 minutes under the room temperature, add 5-chloro-1-(4-trifluoromethyl-phenyl)-pentane-1-ketone of 1 equivalent (15mmol), add 1 normal sodium iodide then.This mixture was stirred 20 hours down in 80 ℃.Evaporation removes and desolvates, and residuum is dissolved in the 100ml methylene dichloride.
Wash organic layer with water, and use dried over mgso, then evaporation.With column chromatography purifying residuum, so obtain ketone-derivative 3ii of 6.4mmol, it is dissolved in 30ml methyl alcohol.Add 1 normal O-(2-amino-ethyl)-oxyamine two-HCl salt toward this solution, and this mixture was heated 12 hours down in 80 ℃.Behind the evaporating solvent, residuum is dissolved in methylene dichloride, and washes with water.Use the dried over mgso organic layer, and evaporating solvent obtains residuum, be purified with column chromatography.After being added to this pure substance, 3 normal HCl in ethanol obtain three HCl-salt of compound 3.
Mp.156-60 ℃; Overall yield 15%.
The synthetic of compound 7 is the two-step reaction that originates in 2-sec.-propyl oxygen base-phenylpiperazine (7i).7i is suspended in the 40ml acetonitrile with the 4.2mmol phenylpiperazine.Add 2 normal DIPEA, 1 normal 4-chloro-1-(4-trifluoromethyl-phenyl)-butane-1-ketone and 1 normal potassiumiodide.This mixture backflow is spent the night, and at second day evaporating solvent.With column chromatography purifying residuum, obtain pure ketone-compound 7ii of 2.5mmol, it is dissolved in 30ml ethanol (100%) once more.Add 1 normal O-(2-amino-ethyl) oxyamine two-HCl salt and 1 normal pyridine.This mixture was heated 4 hours down in 80 ℃.With column chromatography purifying residuum, so obtain the 2mmol orange oil behind the evaporating solvent.This oily mater is dissolved in ethanol, and adds 1 normal fumaric acid.Obtain the amorphous fumarate of compound 7 after the evaporation; Overall yield 50%
The synthetic of compound 8 is the two-step reaction that originates in 4-(2,3 dihydros-1,4 benzo dioxine-5-yl)-1-piperazine (3i).The phenylpiperazine (3i) of 3.5mmol is suspended in the 40ml acetonitrile.Add 2 normal DIPEA, 1 normal 6-chloro-1-(4-trifluoromethyl-phenyl)-hexane-1-ketone and 1 equivalent potassiumiodide.This mixture backflow is spent the night, and at second day evaporating solvent.With column chromatography purifying residuum, obtain pure ketone-compound 8ii of 1.7mmol, it is dissolved in 10ml ethanol (100%) once more.Add 1 normal O-(2-amino-ethyl) oxyamine, two HCl salt, and this mixture was heated 4 hours down in 80 ℃.With column chromatography purifying residuum, so obtain the 1.6mmol yellow oil behind the evaporating solvent.Oily mater is dissolved in ethanol, and adds 2 normal fumaric acid.Obtain the amorphous fumarate of compound 8 after the evaporation; Overall yield 45%.
Compound 9 synthesize the two-step reaction that originates in 4-(2,3 dihydros-1,4 benzo dioxine-5-yl)-1-piperazine.Compound 3ii (30mmol) is dissolved in the methyl alcohol of 20ml.Add 1 normal O-(N-methyl-2-amino-ethyl)-oxyamine two-HCl salt toward this solution, and this mixture was heated 5 hours down in 80 ℃.Behind the evaporating solvent, residuum is dissolved in methylene dichloride, and, uses the salt water washing then with the sodium hydrogen carbonate solution washing.Use the dried over mgso organic layer, and evaporating solvent obtains residuum, be purified by column chromatography.The ethanolic soln of 1 normal fumaric acid is added to the material of purifying, then obtains the fumarate of compound 9 after the evaporating solvent; Overall yield 15%.
The synthetic of compound 10 is the two-step reaction that originates in 4-(2,3 dihydros-1,4 benzo dioxine-5-yl)-1-piperazine (3i).3i is suspended in the 40ml acetonitrile with the 6mmol phenylpiperazine.Add 2 normal DIPEA, 1 normal 7-chloro-1-(4-trifluoromethyl-phenyl)-heptane-1-ketone and 1 equivalent potassiumiodide.This mixture backflow is spent the night, and at second day evaporating solvent.With column chromatography purifying residuum, obtain the pure ketone of 4.2mmol-compound 10ii, it is dissolved in the ethanol (100%) of 25ml once more.Add 1 normal O-(2-amino-ethyl) oxyamine two-HCl salt, and this mixture was heated 4 hours down in 80 ℃.With column chromatography purifying residuum, so obtain the 2mmol yellow oil behind the evaporating solvent.This oily mater is dissolved in ethanol, and adds 1.5 equivalent fumaric acid.Obtain the amorphous fumarate of compound 10 after the evaporation; Overall yield 35%.
The compound of table 1. general formula (1)
Wherein Q can be one of structure fragment A-N
Compound | y | R 1 | Q | x | R 2 | R 3 | R 4 | n | m | mp(℃) |
3 | - | - | A | 1 | 4-CF 3 | H | H | 3 | 1 | 156-160 |
4 | 1 | 2-OMe | N | 1 | 4-F | H | H | 2 | 1 | 150-152 |
5 | - | - | F | 1 | 4-CF 3 | H | H | 3 | 1 | 158 |
6 | - | - | D | 1 | 4-CF 3 | H | H | 3 | 1 | 153-154 |
7 | 1 | OCH(Me) 2 | N | 1 | 4-CF 3 | H | H | 2 | 1 | Amorphous |
8 | - | - | A | 1 | 4-CF 3 | H | H | 4 | 1 | Amorphous |
9 | - | - | A | 1 | 4-CF 3 | Me | H | 3 | 1 | Amorphous |
10 | - | - | A | 1 | 4-CF 3 | H | H | 5 | 1 | Amorphous |
11 | 1 | 2-OMe | N | 1 | 4-CF 3 | H | H | 5 | 1 | Amorphous |
Synthetic as above-mentioned particular compound is intended to further illustration the present invention in more detail.Therefore they are not considered to limit the scope of the invention by any way.Other embodiment of the present invention is conspicuous for the those skilled in the art that considered explanation of the present invention disclosed herein and enforcement.Therefore this specification sheets and embodiment are intended to be regarded as merely and exemplify, and this true scope and design are represented by claim.
Embodiment 3: the preparation that is used for the compound 3 of zooscopy
For carrying out oral (p.o.) administration: the solid chemical compound 3 toward the desired amt in Glass tubing (0.5-5mg) adds some granulated glass spherees, and by vortex 2 minutes solid is pulverized.After the solution of the Poloxamer188 (Lutrol F68) of 1% methylcellulose gum and 2% (v/v) of adding 1ml in water, came suspended compound in 10 minutes by vortex.Regulate pH to 7 with the several NaOH aqueous solution (0.1N).Further be suspended in remainder particulate in the suspension with ultra sonic bath.
For carrying out intraperitoneal (i.p.) administration: add some granulated glass spherees toward the desired amt in glass (0.5-15mg) solid chemical compound 3, and solid is pulverized by vortex 2 minutes.Add after 1% methylcellulose gum and the solution of 5% N.F,USP MANNITOL of 1ml in water, came suspended compound in 10 minutes by vortex.At last with pH regulator to 7.
Embodiment 4: the pharmacology test result
In following table, shown the Dopamine HCL-D that obtains according to above-described scheme
2With serotonin reuptake acceptor avidity data.
The external avidity of table 2. The compounds of this invention
External avidity | ||
Dopamine HCL-D 2 | The 5-HT reuptake | |
Compound | pK i | pK i |
3 | 8.3 | 8.2 |
4 | 8.6 | 7.3 |
5 | 8.2 | 8.3 |
6 | 6.6 | 8.3 |
7 | 8.1 | 7.0 |
8 | 8.3 | 8.0 |
9 | 8.4 | 7.5 |
10 | 8.4 | 8.5 |
11 | 8.3 | 8.3 |
Claims (10)
1. the compound of general formula (1) and tautomer thereof, steric isomer and N-oxide compound, and acceptable salt, hydrate and solvate on the pharmacology of the compound of this formula (1) and tautomer, steric isomer and N-oxide compound:
Wherein:
M and n are 1,2,3,4,5,6,7 or 8 independently,
X is 0,1,2 or 3,
R
2Be halogen, branched-chain or straight-chain alkyl (C
1-6), phenyl, benzyl, side chain or straight chain alkoxyl group (C
1-6), trifluoromethyl or cyano group,
R
3And R
4Represent hydrogen, alkyl (C independently
1-6), phenyl, benzyl or ethanoyl,
Group Q is selected from structure fragment A-N
Wherein:
Y is 1,2 or 3,
R
1Be halogen, branched-chain or straight-chain alkyl (C
1-6), phenyl, benzyl, side chain or straight chain alkoxyl group (C
1-6), trifluoromethyl or cyano group.
2. the compound of the desired general formula of claim 1 (1) and tautomer thereof, steric isomer and N-oxide compound, and acceptable salt, hydrate and solvate on the pharmacology of the compound of this formula (1) and tautomer, steric isomer and N-oxide compound, wherein m is 1, n is 2,3,4 or 5, x is 1, R
2Be 4-fluorine or 4-trifluoromethyl, R
3And R
4Represent hydrogen or methyl independently, group Q is selected from structure fragment A, D, F or N, and y is 1, R
1Be side chain or straight chain alkoxyl group (C
1-3).
3. be selected from desired compound of following claim 1 and tautomer thereof, steric isomer and N-oxide compound, and acceptable salt, hydrate and solvate on the pharmacology of the compound of this formula (1) and tautomer, steric isomer and N-oxide compound:
Those symbols in the symbology formula (1) wherein:
With structure fragment A, D, F or N:
4. pharmaceutical composition comprises pharmaceutically acceptable carrier and/or at least a acceptable accessories and as the compound or its salt of one of at least a claim 1-3 of the pharmacological activity amount of activeconstituents.
5. the desired preparation of compositions method of claim 4 is characterized in that the compound or its salt of one of at least a claim 1-3 is made the form that is suitable for administration.
6. the desired compound or its salt arbitrarily of claim 1-3 is used as medicine.
7. the arbitrarily desired compound of claim 1-3 is used to prepare the application of the pharmaceutical composition of treatment CNS disease.
8. claim 7 desired application is characterized in that this disease is attack, anxiety disorder, autism, dizzy, depressed, cognition or dysmnesia, Parkinson's disease, schizophrenia and other mental disorder.
9. claim 7 desired application is characterized in that this disease is for depressed.
10. claim 7 desired application is characterized in that this disease is schizophrenia and other mental disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04106350 | 2004-12-07 | ||
EP04106350.4 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101072765A true CN101072765A (en) | 2007-11-14 |
Family
ID=34930004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800420702A Pending CN101072765A (en) | 2004-12-07 | 2005-12-06 | Phenylpiperazines with a combination of affinity for dopamine -D2 receptors and serotonin reuptake sites |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1828161A2 (en) |
JP (1) | JP2008523026A (en) |
KR (1) | KR20070091646A (en) |
CN (1) | CN101072765A (en) |
AR (1) | AR052258A1 (en) |
AU (1) | AU2005313386A1 (en) |
BR (1) | BRPI0518370A2 (en) |
CA (1) | CA2587928A1 (en) |
MX (1) | MX2007006756A (en) |
RU (1) | RU2007125636A (en) |
SA (1) | SA05260389B1 (en) |
TW (1) | TW200633987A (en) |
WO (1) | WO2006061372A2 (en) |
ZA (1) | ZA200704151B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
US8063062B2 (en) | 2006-12-20 | 2011-11-22 | Solvay Pharmaceuticals B.V. | Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition |
US8138174B2 (en) | 2007-01-10 | 2012-03-20 | Solvay Pharmaceuticals B.V. | Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition |
EA200970672A1 (en) * | 2007-01-10 | 2010-02-26 | Солвей Фармасьютикалс Б.В. | CONNECTIONS WITH THE COMBINATION OF CANNABINOID-SWANTAGONISM AND INHIBITION OF SEROTONIN REVERSE CAPTURE |
CN101918382A (en) * | 2008-01-15 | 2010-12-15 | 雅培卫生保健产品有限责任公司 | Bifeprunox derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2162312B1 (en) * | 1971-12-10 | 1975-02-07 | Buzas Andre | |
EP0189612B1 (en) * | 1984-12-21 | 1992-11-04 | Duphar International Research B.V | New pharmaceutical compositions having a psychotropic activity |
AU772189B2 (en) * | 1999-08-23 | 2004-04-08 | Solvay Pharmaceuticals B.V. | New phenylpiperazines |
AR032712A1 (en) * | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | A MESILATE OF PHENYLPIPERAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT |
-
2005
- 2005-12-06 JP JP2007544892A patent/JP2008523026A/en not_active Withdrawn
- 2005-12-06 MX MX2007006756A patent/MX2007006756A/en unknown
- 2005-12-06 RU RU2007125636/04A patent/RU2007125636A/en not_active Application Discontinuation
- 2005-12-06 CA CA002587928A patent/CA2587928A1/en not_active Abandoned
- 2005-12-06 CN CNA2005800420702A patent/CN101072765A/en active Pending
- 2005-12-06 SA SA05260389A patent/SA05260389B1/en unknown
- 2005-12-06 AR ARP050105090A patent/AR052258A1/en not_active Application Discontinuation
- 2005-12-06 KR KR1020077015625A patent/KR20070091646A/en not_active Application Discontinuation
- 2005-12-06 AU AU2005313386A patent/AU2005313386A1/en not_active Abandoned
- 2005-12-06 EP EP05819231A patent/EP1828161A2/en not_active Withdrawn
- 2005-12-06 WO PCT/EP2005/056500 patent/WO2006061372A2/en active Application Filing
- 2005-12-06 TW TW094142933A patent/TW200633987A/en unknown
- 2005-12-06 BR BRPI0518370-7A patent/BRPI0518370A2/en not_active IP Right Cessation
-
2007
- 2007-05-22 ZA ZA200704151A patent/ZA200704151B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200633987A (en) | 2006-10-01 |
ZA200704151B (en) | 2008-08-27 |
CA2587928A1 (en) | 2006-06-15 |
MX2007006756A (en) | 2007-11-09 |
AU2005313386A1 (en) | 2006-06-15 |
JP2008523026A (en) | 2008-07-03 |
AR052258A1 (en) | 2007-03-07 |
RU2007125636A (en) | 2009-01-20 |
SA05260389B1 (en) | 2009-06-09 |
KR20070091646A (en) | 2007-09-11 |
BRPI0518370A2 (en) | 2008-11-18 |
WO2006061372A2 (en) | 2006-06-15 |
EP1828161A2 (en) | 2007-09-05 |
WO2006061372A3 (en) | 2006-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5576318A (en) | Benzimidazolone derivatives | |
JP2008523031A (en) | Phenylpiperazine derivatives exhibiting a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | |
KR20080046205A (en) | N-oxides as prodrugs of piperazine & piperidine derivatives | |
CN101072765A (en) | Phenylpiperazines with a combination of affinity for dopamine -D2 receptors and serotonin reuptake sites | |
AU666212B2 (en) | Novel piprazine carboxamides | |
CN101072563A (en) | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites | |
JP3520177B2 (en) | Serotonin 5-HT3 receptor partial activator | |
PL183526B1 (en) | N-substituted derivatives of 3-azabicyclo [3.2.0] heptane, method of obtaining them and their application | |
JPS6377856A (en) | Novel phanyl, pyrrolidine-2-yl-substituted 5-member heterocyclic compound, manufacture and medicinal composition | |
AU2002250983B2 (en) | 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site | |
AU730650B2 (en) | Benzimidazole derivative | |
CN1128030A (en) | Heterocyclic amines having central nervous system activity | |
JPH0372061B2 (en) | ||
CN101072770A (en) | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | |
US20060122177A1 (en) | Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | |
US7371769B2 (en) | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | |
JP2003514764A (en) | Aryl- {4-fluoro-4-[(2-pyridin-2-ylethylamino) methyl] piperidin-1-yl) methanone derivatives as 5-HT1 receptor agonists | |
WO2000018763A2 (en) | 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1109399 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071114 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1109399 Country of ref document: HK |